Remove 2029 Remove Competition Remove Patients Remove Pharma
article thumbnail

NICE recommends AbbVie’s/J&J’s Imbruvica for combo use in untreated CLL

Pharmaceutical Technology

There, the data shows that patients on this regimen live longer lives along with having a greater period of time before disease progression, than with other treatments. CLL is regarded as the most common type of leukaemia in England where 3,157 patients were diagnosed with the disease in 2017, based on the institute’s announcement.

article thumbnail

J&J builds case for antidepressant Spravato with head-to-head trial

pharmaphorum

The phase 3 ESCAPE-TRD study in 676 patients revealed that significantly more of those treated with Spravato were able to achieve remission from symptoms of depression without a relapse over 32 weeks of follow-up compared to quetiapine. and 17.6%, respectively, according to J&J’s pharma unit Janssen. and 14.1%, respectively.

Sales 52
article thumbnail

Intercept receives orphan drug designation for liver disease combo therapy

Pharmaceutical Technology

Orphan drug designations are granted to drugs that target rare disorders with fewer than 200,000 patients in the US. Primary biliary cholangitis is a rare autoimmune disease where small bile ducts are injured by the patient’s own immune system. billion in 2029. This results in bile buildup in the liver and can lead to scarring.